Active Studies

The primary objectives of this study are to evaluate the effect of Obeticholic Acid
treatment compared to placebo on 1) histological improvement and 2) liver-related clinical
outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver
fibrosis.

This feasibility study will assess the effects of the Nativis Voyager therapy in patients
with recurrent GBM who have either failed standard of care or are intolerant to therapy. The
study will enroll and treat up to 64 subjects of which 32 will be treated with the Voyager
therapy alone (monotherapy) and 32 will be treated with Voyager plus concurrent
chemotherapy. Safety and clinical utility will be evaluated.

The purpose of this study is to determine the safety and efficacy of bilateral intramuscular
injections of VM202 versus placebo in the treatment of painful diabetic neuropathy.

A total of 477 subjects will be randomized in a 2:1 ratio to one of two treatment groups:

Treatment - VM202 - 318 subjects Control - Placebo (VM202 vehicle) - 159 subjects

Randomization will be stratified by current use of gabapentin and/or pregabalin.

This study evaluates the tolerability, safety and activity of SRX246 in the treatment of
irritability in patients with Huntington's disease. Two-thirds of all participants will
receive SRX246, while the other third will receive a placebo.

The purpose of this study is to determine how safe and effective the study drug Olokizumab
is, in patients with Rheumatoid Arthritis (RA) who are already receiving, but not fully
responding to treatment with an existing medication called a tumour necrosis factor alpha
inhibitor

Pages